A convergent trend is emerging across three research fronts—synaptic fluid biomarkers, computational brain network modeling, and AI-driven behavioral phenotyping—all aimed at solving the same problem: earlier, more precise, and more mechanistically grounded detection and stratification of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The synaptic biomarker literature, synthesized across 65 study cohorts, converges on a core panel of consistently altered proteins (SNAP-25, GAP-43, Synaptotagmin-1, Syntaxin-1B, Neuronal Pentraxin Receptor/1/2) detectable in both CSF and blood across the AD-dementia and MCI spectrum. These synaptic markers are positioned not only as diagnostic tools but as mechanistic anchors for neuroprotective interventions, reflecting a shift from amyloid/tau-centric biomarkers toward synaptic integrity as a therapeutic and monitoring target.
In parallel, a computational neuroimaging trend combines graph theory–derived topological parameters with virtual brain modeling–derived dynamical parameters to build subject-specific phenotypes of MCI. These combined multiparametric signatures correlate strongly with established pathology (amyloid-beta, tau) and with cognitive performance (MMSE, R²~70%), suggesting that network-level and dynamical brain modeling can serve as intermediate, mechanistically interpretable biomarkers bridging molecular pathology and clinical symptomatology. This reflects a broader movement toward personalized, model-based stratification of prodromal dementia rather than reliance on categorical diagnosis alone, though machine learning approaches (e.g., CatBoost) still struggle with the inherent heterogeneity of MCI as a diagnostic category.
A third, more applied trajectory concerns non-invasive digital phenotyping via handwriting and drawing analysis, using deep learning architectures (CNNs, multimodal Transformers) to extract cognitive/digital biomarkers from tasks like clock drawing, achieving near-90% accuracy in distinguishing AD, MCI, and healthy controls. While promising as scalable, low-cost screening tools, this field is systematically limited by small, single-center sample sizes and absence of longitudinal validation, constraining clinical translation—paralleling limitations seen in antidiabetic drug repurposing trials (metformin, pioglitazone, GLP-1 receptor agonists), where systematic reviews of 11 studies find only modest, inconsistent evidence (e.g., metformin's episodic memory benefit in metabolically vulnerable subgroups) rather than robust neuroprotection.
Collectively, these threads depict a field moving toward multimodal, mechanistically layered characterization of AD/MCI—linking molecular synaptic degeneration, network-level brain dysfunction, and behaviorally captured digital signatures—while candidate repurposed pharmacotherapies remain exploratory. The unifying trajectory is toward integrative, personalized diagnostic pipelines that combine fluid biomarkers, computational brain modeling, and AI-based behavioral assays, with the major bottleneck being validation at scale: larger multicenter cohorts, longitudinal designs, and harmonized biomarker-phenotype-treatment linkage needed before neuroprotective and digital diagnostic strategies can be clinically deployed.